Variation in response rates to isolated limb perfusion in different soft-tissue tumour subtypes: an international multi-centre study

Eur J Cancer. 2023 Sep:190:112949. doi: 10.1016/j.ejca.2023.112949. Epub 2023 Jun 20.

Abstract

Objective: The aim of this study was to investigate the response rates of different extremity soft-tissue sarcoma subtypes (eSTS) after isolated limb perfusion (ILP), based on an international multi-centre study.

Materials and methods: The retrospective cohort comprised eSTS patients from 17 specialised ILP centres that underwent melphalan-based ILP, with or without recombinant human tumour necrosis factor (rhTNFα) (TM-ILP and M-ILP, respectively). Response was measured on imaging (magnetic resonance imaging) and/or clinical response, for which M-ILPs were excluded.

Results: A total of 1109 eSTS patients were included. The three most common histological subtypes were undifferentiated pleomorphic sarcoma (17%, n = 184), synovial sarcoma (16%, n = 175) and myxofibrosarcoma (8%, n = 87). rhTNFα was used in 93% (TM-ILP) and resulted in a significantly better overall response rate (ORR, p = 0.031) and complete responses (CR, p < 0.001) in comparison to M-ILP, without significant differences among histological subgroups. The ORR of TM-ILP was 68%, including 17% CR. Also, 80% showed progressive disease. Significantly higher response rates were shown for Kaposi sarcoma (KS) with 42% CR and 96% ORR (both p < 0.001), and significantly higher CR rates for angiosarcoma (AS, 45%, p < 0.001) and clear cell sarcoma (CCS, 31%, p = 0.049). ILP was followed by resection ≤ 6 months in 80% of the patients. The overall limb salvage rate was 88%, without significant differences among histological subgroups, but was significantly higher for ILP responders compared to non-responders (93% versus 76%, p < 0.001).

Conclusion: ILP resulted in high response and LRS among all eSTS subtypes, however, with significant differences between subtypes with most promising results for KS, AS and CCS.

Keywords: ILP; Isolated limb perfusion; Response evaluation; Soft-tissue sarcoma.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Antineoplastic Agents, Alkylating / therapeutic use
  • Chemotherapy, Cancer, Regional Perfusion / methods
  • Extremities / pathology
  • Humans
  • Melphalan / therapeutic use
  • Perfusion
  • Retrospective Studies
  • Sarcoma* / pathology
  • Sarcoma, Kaposi*
  • Soft Tissue Neoplasms* / pathology
  • Tumor Necrosis Factor-alpha

Substances

  • Melphalan
  • Tumor Necrosis Factor-alpha
  • Antineoplastic Agents, Alkylating